Clinical Trials Logo

Clinical Trial Summary

In this study the investigators would like to investigate the degree of damage of the synapses, an important part of the neurons vital for the communications between neurons, in Multiple System Atrophy (MSA).


Clinical Trial Description

Multiple System Atrophy (MSA) is a chronic and progressive neurological disease, for which unfortunately there is no cure yet. It is known from pathological studies that the synapses (the terminal parts of the neurons) are affected in this disease, but the investigators don't know how, and how much this happens. An imaging tool called Positron Emission Tomography (PET) can study the integrity of the synapses by the use of a dedicated tracer, called [11C]UCB-J. In this study the investigators would like to study how, and how early, the synapse deteriorate in patients with MSA. For this study, patients with the MSA-P form of disease will be enrolled. Participants will be asked to undergo a clinical visit with questionnaires and scales for motor and cognitive symptoms. Then, participants will come for a [11C]UCB-J PET scan, a [18F]FDG PET scan, to check the metabolism of the brain, and a MRI scan, to help the analysis of the PET. The participants will also be asked to perform a Lumbar puncture for a cerebrospinal fluid draw. This procedure will be optional. The results will help in understanding better the mechanisms underlying this disease and open new avenues for its treatment. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05121012
Study type Observational
Source University of Exeter
Contact Edoardo R. de Natale, MD MSc Ph.D
Phone 07503741242
Email [email protected]
Status Recruiting
Phase
Start date September 1, 2021
Completion date September 1, 2024

See also
  Status Clinical Trial Phase
Recruiting NCT03593512 - Deep Brain Stimulation for Autonomic and Gait Symptoms in Multiple System Atrophy N/A
Recruiting NCT03648905 - Clinical Laboratory Evaluation of Chronic Autonomic Failure Phase 1
Recruiting NCT02897063 - Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure Phase 1
Not yet recruiting NCT00758849 - Fipamezole in Neurogenic Orthostatic Hypotension Phase 2
Completed NCT01155492 - Increased Gut Permeability to Lipopolysaccharides (LPS) in Parkinson's Disease N/A
Recruiting NCT04431713 - Exenatide Once-weekly as a Treatment for Multiple System Atrophy Phase 2
Completed NCT04184063 - Study of NBMI Treatment in Patients With Atypical Parkinsons (PSP or MSA) Phase 2
Terminated NCT03589976 - A Futility Trial of Sirolimus in Multiple System Atrophy Phase 2
Recruiting NCT04706234 - Systematic Assessment of Laryngopharyngeal Function in Patients With MSA, PD, and 4repeat Tauopathies
Completed NCT00368199 - Transcranial Duplex Scanning and Single Photon Emission Computer Tomography (SPECT) in Parkinsonian Syndromes N/A
Recruiting NCT04472130 - Neurodegenerative Diseases Registry
Recruiting NCT04876326 - Potential Use of Autologous and Allogeneic Mesenchymal Stem Cells in Patients With Multiple System Atrophy N/A
Completed NCT03753763 - Safinamide for Multiple System Atrophy (MSA) Phase 2
Recruiting NCT04250493 - Insulin Resistance in Multiple System Atrophy N/A
Terminated NCT02149901 - Water and Sudafed in Autonomic Failure Early Phase 1
Terminated NCT00997672 - Lithium in Multiple System Atrophy Phase 2
Completed NCT00465790 - Research of Biomarkers in Parkinson Disease Phase 0
Terminated NCT00547911 - Augmenting Effects of L-DOPS With Carbidopa and Entacapone Phase 1/Phase 2
Completed NCT00001549 - Diagnosis and Natural History Study of Patients With Neurological Conditions N/A
Recruiting NCT04620382 - Effect of Midodrine vs Abdominal Compression on Cardiovascular Risk Markers in Autonomic Failure Patients Early Phase 1